High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. 1998

F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
Department of Medical Oncology, University Hospital-Terni, Italy.

Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B). Six weekly doses were considered one course. One hundred eighty-two patients were randomized in this trial and 162 (89%) were evaluable for response: 81 patients in arm A and 81 patients in arm B. Objective response was observed in 18 (one complete response and 17 partial responses) of 81 evaluable patients (22%; 95% confidence interval, 13-31%) in arm A, and 24 (nine complete responses and 15 partial responses) of 81 patients (30%; 95% confidence interval, 20-40%) in arm B. There was no difference in terms of median time to progression and median survival. Gastrointestinal toxicity was the most frequently observed toxicity in both arms. The double modulation of 5FU, FA plus HU does not appear to be better than the classic 5FU plus FA schedule. This trial confirms that 5FU and FA reached a plateau of 20% to 30%.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
January 1991, Journal of surgical oncology. Supplement,
F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
May 1992, Annals of oncology : official journal of the European Society for Medical Oncology,
F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
June 1996, American journal of clinical oncology,
F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
January 1988, Cancer investigation,
F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
June 1996, American journal of clinical oncology,
F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
November 1995, Cancer,
F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
January 1988, Advances in experimental medicine and biology,
F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
September 1988, European journal of cancer & clinical oncology,
F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
October 1995, Cancer,
F Di Costanzo, and S Gasperoni, and P Malacarne, and V Belsanti, and G Luppi, and M Marzola, and E Corgna, and A Sdrobolini, and R Passalacqua, and F Figoli, and R Algeri, and S Zironi, and S Angiona, and C Boni
October 1985, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Copied contents to your clipboard!